fbpx

Novel Eye Drop to Relieve Presbyopia Enters Phase 3 Clinicals

Orasis Pharmaceuticals, an Israeli based  ophthalmic pharmaceutical company announced the start of Phase 3 clinical studies in the US to evaluate novel eye drop candidate, CSF-1, designed to provide temporary correction of presbyopia.

The proprietary eye drop exerts its pharmacological action through pupil modulation. In clinical trials, the medication was dosed twice daily allowing patients to choose how and when to use it.

According to information provided by the company, the eye drop candidate is a proprietary combination of low-dose pilocarpine combined with multi-faceted vehicles designed to achieve the optimal balance between efficacy, safety and comfort.

The ophthalmological use of pilocarpine is well known. The side effect profile of pilocarpine includes eye irritation, temporary blurred vision, poor vision in low light, and headache or brow ache.

The company told Optik, “Clinical trials to date have demonstrated CSF-1 being a well-tolerated formulation with only mild and temporary adverse events.” 

Further, a Phase 2 study completed at the end of 2019 showed no impact on distance or night vision, according to the company. 

The Phase 3 studies are multi-centre, double-masked, parallel-group clinical trials in the US enrolling approximately 600 participants with presbyopia to further evaluate the efficacy and safety of CSF-1.

Upon completion of these studies and FDA approval the company will explore launches in additional countries. No specific plans for commercialization in Canada were provided upon request. 

One day, patients may opt to preemptively instil an eye drop instead of fumbling to find readers to view the fine print on a menu.

About Orasis Pharmaceuticals
Orasis is an emerging ophthalmic pharmaceutical company committed to making near vision clear again for people with presbyopia. Orasis’ novel proprietary formulation, designed to achieve an optimal balance between efficacy, safety and comfort, has the potential to position the company as an emerging leader in the presbyopia space. Orasis is based in Herzliya, Israel. For more information, visit https://www.orasis-pharma.com 

Featured Posts

Myopia Profile Visitor Data Indicates Surging Global Interest in Research, Interventions, and Clinical Practice

Professional and Parent Website Use Reveals Record Engagement and Impact

Learn More
Appoint of Louise Courville

Louise Courville Appointed to the VuePoint Team

Louise Courville appointed to spearhead growth initiatives of VuePoint publications and services.

Read more

Transitions ® GEN S – Now Available in Canada

Transitions® GEN S™, the ultra-responsive to light lens from Transitions Optical has launched in Canada.

Read more

CooperVision Extends Partnership with Plastic Bank, Adds Vision Care Program for Collectors

Collaboration Expands Support for People + Planet

Read more
Nikon Optical Canada logo

Nikon Optical Canada Launches Transitions® GEN S™ – Pushing Innovation Even Further

Nikon Optical Canada introduces Transitions® GEN S™ the latest innovation on the market to provide eyeglass lens wearers more than just correction.

Read more

Myopia Profile Visitor Data Indicates Surging Global Interest in Research, Interventions, and Clinical Practice

Professional and Parent Website Use Reveals Record Engagement and Impact

Learn More
Appoint of Louise Courville

Louise Courville Appointed to the VuePoint Team

Louise Courville appointed to spearhead growth initiatives of VuePoint publications and services.

Read More

Transitions ® GEN S – Now Available in Canada

Transitions® GEN S™, the ultra-responsive to light lens from Transitions Optical has launched in Canada.

Read More

CooperVision Extends Partnership with Plastic Bank, Adds Vision Care Program for Collectors

Collaboration Expands Support for People + Planet

Read More
Nikon Optical Canada logo

Nikon Optical Canada Launches Transitions® GEN S™ – Pushing Innovation Even Further

Nikon Optical Canada introduces Transitions® GEN S™ the latest innovation on the market to provide eyeglass lens wearers more than just correction.

Read More

Myopia Profile Visitor Data Indicates Surging Global Interest in Research, Interventions, and Clinical Practice

Professional and Parent Website Use Reveals Record Engagement and Impact

Learn More
Appoint of Louise Courville

Louise Courville Appointed to the VuePoint Team

Louise Courville appointed to spearhead growth initiatives of VuePoint publications and services.

Read more

Transitions ® GEN S – Now Available in Canada

Transitions® GEN S™, the ultra-responsive to light lens from Transitions Optical has launched in Canada.

Read more

CooperVision Extends Partnership with Plastic Bank, Adds Vision Care Program for Collectors

Collaboration Expands Support for People + Planet

Read more
Nikon Optical Canada logo

Nikon Optical Canada Launches Transitions® GEN S™ – Pushing Innovation Even Further

Nikon Optical Canada introduces Transitions® GEN S™ the latest innovation on the market to provide eyeglass lens wearers more than just correction.

Read more

Myopia Profile Visitor Data Indicates Surging Global Interest in Research, Interventions, and Clinical Practice

Professional and Parent Website Use Reveals Record Engagement and Impact

Learn More
Appoint of Louise Courville

Louise Courville Appointed to the VuePoint Team

Louise Courville appointed to spearhead growth initiatives of VuePoint publications and services.

Read more

Transitions ® GEN S – Now Available in Canada

Transitions® GEN S™, the ultra-responsive to light lens from Transitions Optical has launched in Canada.

Read more

CooperVision Extends Partnership with Plastic Bank, Adds Vision Care Program for Collectors

Collaboration Expands Support for People + Planet

Read more
Nikon Optical Canada logo

Nikon Optical Canada Launches Transitions® GEN S™ – Pushing Innovation Even Further

Nikon Optical Canada introduces Transitions® GEN S™ the latest innovation on the market to provide eyeglass lens wearers more than just correction.

Read more